GH Research PLC (GHRS) vs Kailera Therapeutics, Inc. (KLRA)
A side-by-side comparison of GH Research PLC and Kailera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GHRS
GH Research PLC
$21.59HealthcareDelayed quote: Oct 6, 2026, 10:24 AM EDT
KLRA
Kailera Therapeutics, Inc.
$10.46HealthcareDelayed quote: Oct 6, 2026, 10:24 AM EDT
Total return — GHRS vs KLRA
growth of $100 · dividends reinvested · last 1yGHRS +25.0% (+25.0%/yr)KLRA -58.3% (-58.3%/yr)GHRS compounded faster over this window
GHRS KLRA
GHRS vs KLRA: by the numbers
- •GHRS is the larger company ($1.48B vs $1.36B market cap).
Metrics side by side
Valuation
| Metric | GHRS | KLRA |
|---|---|---|
| P/B ratio | 4.12 | 1.21 |
Profitability
| Metric | GHRS | KLRA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -17.32% | N/A |
| ROIC | -19.87% | -24.52% |
Growth (annualized)
| Metric | GHRS | KLRA |
|---|---|---|
| Total return CAGR (5Y) | 0.52% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.